Clinical Trial Update: Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides. [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II study of intratumoral CPG 7909 (TLR9 agonist) with local radiation for recurrent mycosis fungoides has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycosis Fungoides

Drugs mentioned

• CPG 7909 (CpG 7909)

Snippet

Sponsor: Stanford University | Conditions: Mycosis Fungoides | Phase 1, Phase 2 | Status: WITHDRAWN